top of page

Understanding Genitourinary Syndrome of Menopause: A Comprehensive Guide

calderkristina
Introduction:

Genitourinary Syndrome of Menopause (GSM) encompasses a spectrum of changes in the lower urinary tract and external genitalia resulting from declining estrogen levels during menopause. Formerly known as vulvovaginal atrophy or urogenital atrophy, GSM represents a significant yet often underdiagnosed aspect of menopausal health [1].


Understanding GSM:

The term "GSM" emerged in 2014 to capture the multifaceted nature of menopausal genital and urinary changes. While GSM predominantly affects postmenopausal women, approximately 15% of premenopausal women may also experience GSM-like symptoms due to hormonal fluctuations [2].


Symptoms of GSM:

GSM symptoms vary widely but often include vaginal dryness, irritation, burning, dyspareunia (painful intercourse), and urinary symptoms such as dysuria and urinary urgency [3,4]. These symptoms not only impact physical comfort but also significantly affect emotional well-being and intimate relationships.





Pathophysiology and Anatomical Effects:

The hypoestrogenic environment of menopause triggers anatomical changes in the genital and urinary tracts. Estrogen receptors, particularly estrogen-b receptors, play a crucial role in maintaining tissue integrity and functionality. However, postmenopausal women primarily exhibit estrogen-b receptors, leading to tissue atrophy, reduced blood flow, and alterations in collagen and elastin levels [1,2,5].




Risk Factors Associated with GSM:

Beyond menopause itself, various risk factors contribute to GSM development, including lifestyle factors such as alcohol abuse and cigarette smoking, as well as medical factors like bilateral oophorectomy and decreased sexual activity. Chronic diseases and low education levels have also been linked to increased GSM risk [4,6, 7].


Diagnosis and Evaluation:

Diagnosing GSM can be challenging, particularly as approximately 50% of postmenopausal women exhibit mild or nonspecific symptoms. Diagnosis typically involves a thorough medical history, pelvic examination, and exclusion of other conditions with similar symptoms [8]. Recent advancements in patient-reported outcome measures (PROMs) specific to genitourinary symptoms have facilitated diagnosis and evaluation [9,10].


Therapeutic Approaches:

GSM management aims at symptom relief and may involve lifestyle modifications, non-hormonal treatments, and hormonal interventions. Lifestyle changes such as smoking cessation can help alleviate symptoms, while non-hormonal therapies like vaginal lubricants and moisturizers offer immediate relief from dryness and discomfort during intercourse [4,11].


In persistent cases, hormonal therapy with estrogen-based products emerges as the "gold standard" treatment option. Locally administered intravaginal estrogen products demonstrate efficacy in alleviating symptoms such as dryness, itchiness, and dyspareunia. Alternative treatments such as intravaginal dehydroepiandrosterone (DHEA), testosterone, and selective estrogen receptor modulators (SERMs) offer additional options for GSM management [2,5,12,13,14].



Conclusion:

GSM represents a complex interplay of hormonal changes, anatomical alterations, and risk factors, significantly impacting the quality of life of affected women. By understanding the pathophysiology, recognizing risk factors, and exploring diverse therapeutic options, women can navigate the challenges of GSM with resilience and empowerment. Through open dialogue with healthcare providers and access to comprehensive care, women can reclaim their comfort, confidence, and intimacy, embracing menopause as a natural phase of life while effectively managing its associated symptoms.


References:

  1. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Portman DJ, Gass ML. Menopause. 2014;21:1063–1068. [PubMed[Google Scholar]

  2. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. Am J Obstet Gynecol. 2016;215:704–711. [PubMed] [Google Scholar]

  3. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Moral E, Delgado JL, Carmona F, et al. Climacteric. 2018;21:167–173. [PubMed] [Google Scholar]

  4. Genitourinary syndrome of menopause. Farrell Am E. http://www.ncbi.nlm.nih.gov/pubmed/28697291Aust Fam Physician. 2017;46:481–484. [PubMed] [Google Scholar]

  5. The recent review of the genitourinary syndrome of menopause. Kim H, Kang SY, Chung YJ, Kim JH, Kim MR. J Menopausal Med. 2015;21:65–71. [PMC free article] [PubMed] [Google Scholar]

  6. Vulvovaginal atrophy. Mac Bride MB, Rhodes DJ, Shuster LT. Mayo Clin Proc. 2010;85:87–94. [PMC free article] [PubMed] [Google Scholar]

  7. Recognizing and treating urogenital atrophy in postmenopausal women. Goldstein I. J Womens Health (Larchmt) 2010;19:425–432. [PubMed] [Google Scholar]

  8. Genitourinary syndrome of menopause: common problem, effective treatments. Phillips NA, Bachmann GA. Cleve Clin J Med. 2018;85:390–398. [PubMed] [Google Scholar]

  9. Measurement properties of patient-reported outcome measures (PROMs) for women with genitourinary syndrome of menopause: a systematic review. Gabes M, Knüttel H, Stute P, Apfelbacher CJ. Menopause. 2019:1342–1353. [PubMed] [Google Scholar]

  10. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Erekson EA, Yip SO, Wedderburn TS, et al. Menopause. 2013;20:973–979. [PMC free article] [PubMed] [Google Scholar]

  11. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. The North American Menopause Society. Menopause. 2013;20:888–902. [PubMed] [Google Scholar]

  12. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. Martel C, Labrie F, Archer DF, et al. J Steroid Biochem Mol Biol. 2016;159:142–153. [PubMed] [Google Scholar]

  13. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Witherby S, Johnson J, Demers L, et al. Oncologist. 2011;16:424–431. [PMC free article] [PubMed] [Google Scholar]

  14. Post-menopausal vulvovaginal atrophy - an overview of the current treatment options. Szymański JK, Siekierski BP, Kajdy A, Jakiel G. Ginekol Pol. 2018;89:40–47. [PubMed] [Google Scholar]

11 views0 comments

Recent Posts

See All

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page